摘要
目的:探讨复方乌梅散对人胃癌SGC-7901细胞株裸鼠移植瘤生长及血管生成相关因子COX-2、VEGF-C表达的影响。方法:将人胃癌细胞SGC-7901通过皮下种植接种于裸鼠腋下,制备裸鼠移植瘤模型,造模成功后随机将裸鼠分为模型组、复方乌梅散小剂量组(10g/kg)、复方乌梅散中剂量组(15g/kg)、复方乌梅散大剂量组(20g/kg),每日灌胃1次,共11次,末次给药后剥离瘤组织称质量,计算移植瘤体积、抑瘤率。应用qRT-PCR检测瘤组织中COX-2和VEGF-C mRNA表达水平。用免疫组织化学法和Western blot法分别检测各组肿瘤组织中COX-2和VEGF-C蛋白的表达。结果:复方乌梅散小剂量组、中剂量组、大剂量组抑瘤率分别为31.83%、34.83%、55.26%,大剂量组抑制肿瘤生长的作用明显增强。免疫组化结果显示复方乌梅散各组移植瘤组织中COX-2和VEGF-C表达均有降低趋势,Western blot结果显示复方乌梅散各组移值瘤组织中COX-2和VEGF-C蛋白表达均呈降低趋势,qRT-PCR检测显示复方乌梅散各组移植瘤COX-2、VEGF-C mRNA的表达明显下调。结论:复方乌梅散可抑制SGC-7901细胞裸鼠移植瘤的生长,抑制COX-2、VEGF-C的表达,且呈剂量依赖性。
Objective: To investigate the effects of Wumeisan(乌梅散,WMS) on growth and angiogenesisrelated factors COX-2,VEGF-C of the human gastric cancer cells SGC-7901 xenografted tumor in nude mice.Methods: Nude mice were implanted with human gastric cancer cells SGC-7901 successfully.All the nude mice were randomly divided into four groups treated with NS,WMS 10 g/kg,WMS 15 g/kg,WMS 20 g/kg by ip injection once every day individually.After the drugs were administered respectively for 11 days,the tumor tissues were collected,tumor weight and the tumor volume were recorded,and tumor inhibitory rate was calculated.RT-PCR was used to determine the expression of COX-2 and VEGF-C m RNA.The expression levels of COX-2 and VEGF-C proteins were detected by immunohistochemistry and Western blotting analysis.Results: The tumor inhibitory rates were 31.83%,34.83%,and 55.26% when treated with WMS 10 g/kg,WMS15 g/kg,WMS 20 g/kg.The group of WMS 20 g/kg could more significantly inhibit the tumor growth(P〈0.05)than the other.The results of immunohistochemical staining showed the expressions of COX-2 and VEGF-C proteins in WMS 20 g/kg group had a more obvious trend of down-regulation.Western blotting analysis showed the similar trend to immunohistochemical.The group of WMS 20 g/kg also caused an inhibitory effect on COX-2 and VEGF-C m RNA expression.Conclusion: WMS had a remarkable inhibitory effect on the growth of transplanted human gastric cancer in nude mice and expression of COX-2 and VEGF-C.
出处
《中医药导报》
2017年第20期25-29,共5页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
国家中医药管理局科研专项项目(JDZX2015090)
江苏省临床医学科技专项(BL2014100)